Overview

Description

  • NatureSynthetic
  • Amino Acid Sequence
    • Amino acids0 to 0

Specifications

Our Abpromise guarantee covers the use of ab44853 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    ELISA

    Western blot

  • Purity> 95 % by SDS-PAGE.

  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Preservative: None
    Constituents: 0.001% Tween 20, 30mM HEPES, 2mM EDTA, 150mM Sodium chloride, pH 6.75

General info

  • Alternative names
    • CLG 3
    • CLG3
    • CLG3
    • Collagenase 3
    • Collagenase 3
    • Collagenase3
    • MANDP1
    • Matrix metallopeptidase 13 (collagenase 3)
    • Matrix Metalloproteinase 13
    • Matrix Metalloproteinase 13
    • Matrix metalloproteinase-13
    • MMP 13
    • MMP-13
    • Mmp13
    • MMP13_HUMAN
    see all
  • FunctionDegrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process.
  • Tissue specificitySeems to be specific to breast carcinomas.
  • Involvement in diseaseDefects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age.
    Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1) [MIM:602111]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.
  • Sequence similaritiesBelongs to the peptidase M10A family.
    Contains 4 hemopexin-like domains.
  • DomainThe conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
  • Cellular localizationSecreted > extracellular space > extracellular matrix.
  • Information by UniProt

References for MMP13 peptide (ab44853)

ab44853 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab44853.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"